{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T05:28:32Z","timestamp":1732339712868,"version":"3.28.0"},"posted":{"date-parts":[[2024,6,20]]},"group-title":"In Review","reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,5,30]]},"abstract":"<title>Abstract<\/title><p>Gastroesophageal adenocarcinoma (GEAC) poses a significant challenge due to its poor prognosis and limited treatment options. Recently, Cancer\/testis antigens (CTAs) have emerged as potential therapy targets due to their high expression in tumor cells and their immunogenic nature. We aimed to explore the expression and co-expression of CTAs in GEAC. We analyzed 63 GEAC patients initially and validated our findings in 329 patients from The Cancer Genome Atlas (TCGA) database. CTA expression was measured after RNA sequencing, while clinical information, including survival outcomes and treatment details, was collected from an institutional database. Co-expression patterns among CTAs were determined using Pearson correlation analysis. The majority of the study cohort were male (87%), Caucasian (94%), and had stage IV disease (64%). CTAs were highly prevalent, ranging from 58\u201319%. The MAGE gene family showed the highest expression, consistent across both cohorts. The correlation matrix revealed a distinct cluster of significantly co-expressed genes, including MAGEA3, NY-ESO-1, and others (0.27\u2009\u2264\u2009r\u2009\u2264\u20090.73). Survival analysis revealed that individual CTAs were associated with poorer survival outcomes in patients not receiving immunotherapy while showing potential for improved survival in those undergoing immunotherapy, although these findings lacked robust reliability. Our study provides a comprehensive characterization of CTA expression and co-expression in GEAC. The strong correlation among CTAs like MAGE, NY-ESO-1, and GAGE suggests a potential for therapies targeting multiple CTAs simultaneously. Further research, including prospective trials, is warranted to assess the prognostic value of CTAs and their suitability as therapeutic targets.<\/p>","DOI":"10.21203\/rs.3.rs-4499622\/v1","type":"posted-content","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T19:34:52Z","timestamp":1718998492000},"source":"Crossref","is-referenced-by-count":0,"title":["Cancer\/testis antigen expression and co-expression patterns in Gastroesophageal Adenocarcinoma"],"prefix":"10.21203","author":[{"given":"Sukumar","family":"Kalvapudi","sequence":"first","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhil Goud","family":"Pachimatla","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Seager","sequence":"additional","affiliation":[{"name":"LabCorp (United States)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Conroy","sequence":"additional","affiliation":[{"name":"LabCorp (United States)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarabjot","family":"Pabla","sequence":"additional","affiliation":[{"name":"LabCorp (United States)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarbajit","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.3390\/jcm9093049","article-title":"Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress","volume":"9","author":"Gambardella V","year":"2020","unstructured":"Gambardella V, et al. Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. J Clin Med. 2020;9(9):3049.","journal-title":"J Clin Med"},{"issue":"15","key":"ref2","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1016\/j.ejca.2013.05.029","article-title":"Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate data","volume":"49","author":"Ronellenfitsch U","year":"2013","unstructured":"Ronellenfitsch U, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer. 2013;49(15):3149\u201358.","journal-title":"Eur J Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"17588359231173177","DOI":"10.1177\/17588359231173177","article-title":"Emerging targets in gastroesophageal adenocarcinoma: what the future looks like","volume":"15","author":"Petrillo A","year":"2023","unstructured":"Petrillo A, Smyth EC, van Laarhoven HWM. Emerging targets in gastroesophageal adenocarcinoma: what the future looks like. Therapeutic Adv Med Oncol. 2023;15:17588359231173177.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/CCO.0000000000000630","article-title":"Multimodality treatment for localized gastric cancer: state of the art and new insights","volume":"32","author":"Petrillo A","year":"2020","unstructured":"Petrillo A, Smyth EC. Multimodality treatment for localized gastric cancer: state of the art and new insights. Curr Opin Oncol. 2020;32(4):347\u201355.","journal-title":"Curr Opin Oncol"},{"key":"ref5","unstructured":"Key Statistics About Stomach Cancer. 2023 January 12, 2022 [cited 2023 December 12,2023]; https:\/\/www.cancer.org\/cancer\/types\/stomach-cancer\/about\/key-statistics.html."},{"key":"ref6","unstructured":"Key Statistics for Esophageal Cancer. 2023 January 12, 2023 [cited 2023 December 12, 2023]; https:\/\/www.cancer.org\/cancer\/types\/esophagus-cancer\/about\/key-statistics.html."},{"year":"2023","author":"Yoon HH","key":"ref7","unstructured":"Yoon HH. Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer. 2023 Oct 31, 2023 [cited 2023 December 12, 2023]; https:\/\/www.uptodate.com\/contents\/initial-systemic-therapy-for-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer?search=gastroesophageal%20adenocarcinoma&source=search_result&selectedTitle=2~52&usage_type=default&display_rank=2."},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired Resistance to Immune Checkpoint Inhibitors","volume":"37","author":"Schoenfeld AJ","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020;37(4):443\u201355.","journal-title":"Cancer Cell"},{"issue":"1","key":"ref9","first-page":"188558","article-title":"Oncogenic cancer\/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","volume":"1876","author":"Yang P","year":"2021","unstructured":"Yang P, Meng M, Zhou Q. Oncogenic cancer\/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021. 1876(1): p. 188558."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"107889","DOI":"10.1016\/j.intimp.2021.107889","article-title":"A novel era of cancer\/testis antigen in cancer immunotherapy","volume":"98","author":"Meng X","year":"2021","unstructured":"Meng X, et al. A novel era of cancer\/testis antigen in cancer immunotherapy. Int Immunopharmacol. 2021;98:107889.","journal-title":"Int Immunopharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1190883","DOI":"10.3389\/fimmu.2023.1190883","article-title":"Cancer\/testis antigens: promising immunotherapy targets for digestive tract cancers","volume":"14","author":"Ai H","year":"2023","unstructured":"Ai H, et al. Cancer\/testis antigens: promising immunotherapy targets for digestive tract cancers. Front Immunol. 2023;14:1190883.","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev-pharmtox-011112-140326","article-title":"Cause and consequence of cancer\/testis antigen activation in cancer","volume":"54","author":"Whitehurst AW","year":"2014","unstructured":"Whitehurst AW. Cause and consequence of cancer\/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol. 2014;54:251\u201372.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.trecan.2018.08.005","article-title":"Emerging contributions of cancer\/testis antigens to neoplastic behaviors","volume":"4","author":"Gibbs ZA","year":"2018","unstructured":"Gibbs ZA, Whitehurst AW. Emerging contributions of cancer\/testis antigens to neoplastic behaviors. Trends cancer. 2018;4(10):701\u201312.","journal-title":"Trends cancer"},{"issue":"54","key":"ref14","doi-asserted-by":"crossref","first-page":"92966","DOI":"10.18632\/oncotarget.21715","article-title":"Genome-wide identification of cancer\/testis genes and their association with prognosis in a pan-cancer analysis","volume":"8","author":"Silva VL","year":"2017","unstructured":"da Silva VL, et al. Genome-wide identification of cancer\/testis genes and their association with prognosis in a pan-cancer analysis. Oncotarget. 2017;8(54):92966.","journal-title":"Oncotarget"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1475-2867-5-4","article-title":"Cancer\/testis antigens and gametogenesis: a review and brain-storming session","volume":"5","author":"Kalejs M","year":"2005","unstructured":"Kalejs M, Erenpreisa J. Cancer\/testis antigens and gametogenesis: a review and brain-storming session. Cancer Cell Int. 2005;5(1):4.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer-testis antigens: putative function, regulation and therapeutic potential","volume":"5","author":"Fratta E","year":"2011","unstructured":"Fratta E, et al. The biology of cancer-testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 2011;5(2):164\u201382.","journal-title":"Mol Oncol"},{"issue":"null","key":"ref17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/ITT.S35570","article-title":"Cancer testis antigen and immunotherapy","volume":"2","author":"Krishnadas DK","year":"2013","unstructured":"Krishnadas DK, Bai F, Lucas KG. Cancer testis antigen and immunotherapy. ImmunoTargets Therapy. 2013;2(null):11\u20139.","journal-title":"ImmunoTargets Therapy"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"e1512329","DOI":"10.1080\/2162402X.2018.1512329","article-title":"Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials","volume":"8","author":"Pol JG","year":"2019","unstructured":"Pol JG, et al. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology. 2019;8(1):e1512329.","journal-title":"Oncoimmunology"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-05-1544","article-title":"Tumor antigen expression in melanoma varies according to antigen and stage","volume":"12","author":"Barrow C","year":"2006","unstructured":"Barrow C, et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res. 2006;12(3):764\u201371.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/bjc.2013.51","article-title":"NY-ESO-1 antibody as a novel tumour marker of gastric cancer","volume":"108","author":"Fujiwara S","year":"2013","unstructured":"Fujiwara S, et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer. 2013;108(5):1119\u201325.","journal-title":"Br J Cancer"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ags3.12406","article-title":"Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study","volume":"5","author":"Imamura Y","year":"2021","unstructured":"Imamura Y, et al. Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study. Ann Gastroenterol Surg. 2021;5(1):46\u201359.","journal-title":"Ann Gastroenterol Surg"},{"issue":"10294","key":"ref22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian YY","year":"2021","unstructured":"Janjigian YY, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"key":"ref23","first-page":"vii","article-title":"Preface. The Siewert Lesson for Adenocarcinomas of the esophagogastric junction: a plea for an order in a complex disease","volume":"182","author":"Schneider PM","year":"2010","unstructured":"Schneider PM. Preface. The Siewert Lesson for Adenocarcinomas of the esophagogastric junction: a plea for an order in a complex disease. Recent Results Cancer Res. 2010;182:vii\u2013viii.","journal-title":"Recent Results Cancer Res"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jmoldx.2017.10.001","article-title":"Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors","volume":"20","author":"Conroy JM","year":"2018","unstructured":"Conroy JM, et al. Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. J Mol Diagn. 2018;20(1):95\u2013109.","journal-title":"J Mol Diagn"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"e0260089","DOI":"10.1371\/journal.pone.0260089","article-title":"A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors","volume":"16","author":"Conroy JM","year":"2021","unstructured":"Conroy JM, et al. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS ONE. 2021;16(12):e0260089.","journal-title":"PLoS ONE"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2018.04.009","article-title":"MAGE-A antigens as targets for cancer immunotherapy","volume":"67","author":"Schooten E","year":"2018","unstructured":"Schooten E, et al. MAGE-A antigens as targets for cancer immunotherapy. Cancer Treat Rev. 2018;67:54\u201362.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ijc.2910630411","article-title":"Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes","volume":"63","author":"Inoue H","year":"1995","unstructured":"Inoue H, et al. Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer. 1995;63(4):523\u20136.","journal-title":"Int J Cancer"},{"issue":"8","key":"ref28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.prp.2017.05.007","article-title":"MAGE-A family is involved in gastric cancer progression and indicates poor prognosis of gastric cancer patients","volume":"213","author":"Lian Y","year":"2017","unstructured":"Lian Y, et al. MAGE-A family is involved in gastric cancer progression and indicates poor prognosis of gastric cancer patients. Pathol - Res Pract. 2017;213(8):943\u20138.","journal-title":"Pathol - Res Pract"},{"issue":"15suppl","key":"ref29","doi-asserted-by":"crossref","first-page":"e14637","DOI":"10.1200\/JCO.2017.35.15_suppl.e14637","article-title":"Phase I study of oncolytic virus (OV) MG1 maraba\/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced\/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214","volume":"35","author":"Jonker DJ","year":"2017","unstructured":"Jonker DJ, et al. Phase I study of oncolytic virus (OV) MG1 maraba\/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced\/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214. J Clin Oncol. 2017;35(15suppl):e14637\u201314637.","journal-title":"J Clin Oncol"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak AD","year":"2016","unstructured":"Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16(9):566\u201381.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/jclinpath-2016-203718","article-title":"MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma: a retrospective clinical study based on tissue microarray","volume":"70","author":"Sang M","year":"2017","unstructured":"Sang M, et al. MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma: a retrospective clinical study based on tissue microarray. J Clin Pathol. 2017;70(6):533\u201340.","journal-title":"J Clin Pathol"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2326-6066.CIR-15-0266","article-title":"Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells","volume":"4","author":"Ohue Y","year":"2016","unstructured":"Ohue Y, et al. Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells. Cancer Immunol Res. 2016;4(12):1049\u201360.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-9966-30-2","article-title":"Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma","volume":"30","author":"Zhou J-x","year":"2011","unstructured":"Zhou J-x, et al. Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma. J Experimental Clin Cancer Res. 2011;30(1):2.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.arcmed.2016.06.001","article-title":"Prognostic Significance of MAGE-A11 in Esophageal Squamous Cell Carcinoma and Identification of Related Genes Based on DNA Microarray","volume":"47","author":"Sang M","year":"2016","unstructured":"Sang M, et al. Prognostic Significance of MAGE-A11 in Esophageal Squamous Cell Carcinoma and Identification of Related Genes Based on DNA Microarray. Arch Med Res. 2016;47(3):151\u201361.","journal-title":"Arch Med Res"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12967-024-04918-0","article-title":"Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer","volume":"22","author":"Seager RJ","year":"2024","unstructured":"Seager RJ, et al. Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer. J Transl Med. 2024;22(1):141.","journal-title":"J Transl Med"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4499622\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4499622\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:43:06Z","timestamp":1732275786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4499622\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":35,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4499622\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1007\/s12032-024-02475-6","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,6,20]]},"subtype":"preprint"}}